Journal article

Therapeutic Breast Reconstruction Using Gene Therapy-Delivered IFN gamma Immunotherapy

Christopher R Davis, Peter A Than, Sacha ML Khong, Melanie Rodrigues, Michael W Findlay, Daniel J Navarrete, Shadi Ghali, Jayant S Vaidya, Geoffrey C Gurtner

Molecular Cancer Therapeutics | AMER ASSOC CANCER RESEARCH | Published : 2020


After mastectomy, breast reconstruction is increasingly performed using autologous tissue with the aim of improving quality of life. During this procedure, autologous tissue is excised, relocated, and reattached using microvascular anastomoses at the site of the extirpated breast. The period during which the tissue is ex vivo may allow genetic modification without any systemic exposure to the vector. Could such access permit delivery of therapeutic agents using the tissue flap as a vehicle? Such delivery may be more targeted and oncologically efficient than systemic therapy, and avoid systemic complications. The cytokine IFNγ has antitumor effects, and systemic toxicity could be circumvented..

View full abstract


Awarded by National Institutes of Health

Funding Acknowledgements

This study was generously supported by the grants from US-UK Fulbright Commission (to C.R. Davis), Royal College of Surgeons of England (to C.R. Davis), National Institutes of Health (RO1 - EB005718-01A1; to G.C. Gurtner), Armed Forces Institute of Regenerative Medicine (to G.C. Gurtner), the Hagey Family Endowed Fund in Stem Cell Research and Regenerative Medicine (to G.C. Gurtner), and the American College of Surgeons (to P.A. Than).